Zepbound (Tirzepatide) Nausea That Won't Go Away: When to Worry and What to Do

How common is nausea on Zepbound, and how severe does it get?

The clearest numbers come from the two pooled placebo-controlled weight-management trials, which ran up to 72 weeks and included 958 patients on placebo, 630 on 5 mg, 948 on 10 mg and 941 on 15 mg [1]. Those two trials are SURMOUNT-1, which randomized 2,539 adults with obesity or overweight and no diabetes to weekly tirzepatide 5, 10 or 15 mg or placebo for 72 weeks, including a 20-week dose-escalation period [2], and SURMOUNT-2, which enrolled 938 adults with a BMI of 27 or higher and type 2 diabetes for 72 weeks of tirzepatide 10 or 15 mg versus placebo [3].

Nausea was reported by 25% on 5 mg, 29% on 10 mg and 28% on 15 mg, versus 8% on placebo [1]. Diarrhea: 19%, 21% and 23% versus 8% [1]. Vomiting: 8%, 11% and 13% versus 2% [1]. Constipation: 17%, 14% and 11% versus 5% [1]. Dyspepsia: 9%, 9% and 10% versus 4% [1]. Any gastrointestinal adverse reaction was reported by 56% of patients on every Zepbound dose, versus 30% on placebo [1].

Severe gastrointestinal reactions were reported in 1.7% of patients on 5 mg, 2.5% on 10 mg and 3.1% on 15 mg, versus 1% on placebo [1]. Treatment was stopped for a gastrointestinal reaction in 1.9%, 3.3% and 4.3% respectively, versus 0.5% on placebo [1].

Wider trial data point the same way. A 2025 systematic review of 26 randomized trials of GLP-1 receptor agonists and dual or triple co-agonists in adults with overweight or obesity and without diabetes found that adverse events were mostly gastrointestinal, most often nausea, vomiting, diarrhea and constipation [4].

What does the label say about the mechanism?

Tirzepatide activates both GIP and GLP-1 receptors and delays gastric emptying; the label says the delay is largest after the first dose and diminishes over time [1]. The half-life is about 5 days, and steady state is reached after 4 weeks of weekly dosing [1].

The label ties the escalation schedule to tolerability: the dose goes up in 2.5 mg increments after at least 4 weeks on the current dose to reduce the risk of gastrointestinal adverse reactions [1].

What the label says about dosing when nausea persists

• The escalation schedule is there to reduce gastrointestinal reactions: 2.5 mg weekly for 4 weeks, then 5 mg, then 2.5 mg steps taken after at least 4 weeks on the current dose [1].
• 2.5 mg is a starting dose only and is not approved as a maintenance dose [1]. Maintenance for weight reduction is 5 mg, 10 mg or 15 mg weekly, with a maximum of 15 mg [1].
• If a maintenance dose is not tolerated, the label says to consider a lower maintenance dose [1].
• Coadministration with another tirzepatide-containing product or with any GLP-1 receptor agonist is not recommended [1].
• Delayed gastric emptying can change how oral medicines are absorbed. The label advises caution with oral drugs and monitoring of drugs that depend on threshold concentrations or have a narrow therapeutic index, such as warfarin [1].

Which label warnings involve nausea and abdominal pain?

Pancreatitis. The label says to observe patients for signs of acute pancreatitis, which may include persistent or severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, the label says to discontinue Zepbound [1]. In the pooled weight trials, adjudication-confirmed acute pancreatitis occurred in 0.2% of Zepbound-treated patients and 0.2% of placebo-treated patients [1].

Gallbladder disease. Cholelithiasis was reported in 1.1% of Zepbound-treated patients versus 1% on placebo, cholecystitis in 0.7% versus 0.2%, and cholecystectomy in 0.2% versus none [1]. Acute gallbladder events were associated with weight reduction. If cholecystitis is suspected, the label says gallbladder studies and clinical follow-up are indicated [1].

Dehydration and kidney injury. Postmarketing reports describe acute kidney injury, in some cases requiring hemodialysis, with the majority of reported events in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea [1]. The label says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1].

Gastroparesis. Zepbound is not recommended in patients with severe gastroparesis [1].

How long is too long?

The label sets no number of weeks after which Zepbound nausea is abnormal. It describes a pattern rather than a cutoff: the majority of nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time [1].